OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
The United States Patent and Trademark Office issued a Notice of Allowance for Zika vaccine patent to GeoVax.
GeoVax announced on Jan. 25, 2023 that the United States Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a Zikv Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”
According to GeoVax, Zika virus (ZIKV) is linked to an increase in microcephaly in infants and neurodegenerative disease, Guillain-Barre syndrome, in adults. The claims to be granted in the patent cover GeoVax’s modified vaccinia Ankara (MVA) vector comprising a nucleic acid sequence encoding a ZZIKV nonstructural (NS1) protein, of which GEO-ZM02 is designed. The company states its MVA platform holds the potential to address the critical unmet need in vaccination of women of childbearing age and newborns against ZIKV.
“Our novel Zika vaccine candidate, GEO-ZM02, is constructed using our modified vaccinia Ankara (MVA) vector platform. Preclinical studies demonstrated a single dose of GEO-ZM02 provided 100% protection against a lethal dose of Zika virus,” stated GeoVax CEO David Dodd, in a company press release. “Addressing many of the world’s most threatening infectious diseases is part of our vision and corporate priorities for MVA’s applications, which also includes an MVA-based next-generation COVID-19 vaccine currently in Phase II clinical trials.”